April 21, 2026
⚑ Important
Regulation
MHLW Issues Final CBN Transition Guidelines for International Brands
The Ministry of Health, Labour and Welfare released comprehensive transition procedures for overseas cannabinoid brands affected by CBN's June 1st Specified Drug designation. International manufacturers must cease Japan-bound CBN product shipments by May 15th to avoid customs seizure. Existing CBN inventory held by licensed importers may be sold until August 31st under supervised disposal protocols. The ministry emphasized that CBG and CBC products remain fully compliant for import, provided THC residue levels stay below 0.001%.
April 22, 2026
Market
CBG Market Demand Surges 340% Following CBN Restriction Announcement
Industry data shows CBG product inquiries from Japanese distributors increased dramatically since the CBN scheduling announcement in February. Major wellness retailers report CBG tinctures and capsules now account for 65% of new cannabinoid product requests. International suppliers indicate 6-8 week lead times for CBG isolate due to unprecedented Japan market demand. Pricing for pharmaceutical-grade CBG has stabilized at ¥45,000-52,000 per kilogram.
April 23, 2026
⚑ Important
Business
Customs Implements Enhanced Certificate Requirements for Cannabinoid Imports
Japan Customs announced strengthened documentation requirements for all cannabinoid imports effective May 1st. Third-party laboratory certificates must now include expanded residual solvent analysis and heavy metals testing according to Japanese Pharmacopoeia standards. Certificate validity reduced from 12 months to 6 months for all hemp-derived ingredients. The changes particularly impact CBD and CBG bulk importers who previously relied on simplified documentation protocols.
📰
Japan Customs
·
customs.go.jp
April 24, 2026
Science
University of Tokyo Publishes CBG Bioavailability Study Results
Researchers at the University of Tokyo's Graduate School of Pharmaceutical Sciences released findings on CBG oral bioavailability in Japanese subjects. The study found CBG absorption rates 23% higher than previously reported in Western populations, potentially due to genetic polymorphisms affecting cytochrome P450 metabolism. Results suggest lower dosing requirements for CBG products targeting the Japanese market. The research provides critical pharmacokinetic data for international brands developing Japan-specific formulations.
April 20, 2026
Regulation
Pharmaceutical Affairs Law Revision Adds CBD Topical Classification
The Ministry of Health, Labour and Welfare clarified regulatory pathways for CBD topical products under revised Pharmaceutical Affairs Law guidelines. CBD concentrations above 2% in topical formulations now require quasi-drug classification and manufacturing facility inspection. Products below 2% CBD maintain cosmetic classification with simplified approval processes. The revision addresses regulatory uncertainty that previously delayed international cosmetic brand entries into Japan's CBD skincare segment.